OncoMatch/Clinical Trials/NCT02960022
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Is NCT02960022 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including enzalutamide and abiraterone acetate for prostate cancer.
Treatment: enzalutamide · abiraterone acetate · prednisone · Leuprolide acetate — The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Prostate Cancer
Demographics
Prior therapy
Must have received: antiandrogen (enzalutamide) — current
Subject must currently be receiving enzalutamide for prostate cancer in a study sponsored by Astellas or Medivation and, based on the investigator's assessment, benefit from continued treatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Site US10052 · Anchorage, Alaska
- Site US10011 · Tucson, Arizona
- Site US10040 · Los Angeles, California
- Site US10009 · Los Angeles, California
- Site US10067 · Orange, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02960022 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received antiandrogen.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages